Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure

Circulation

Volumn 119, Issue 21, 2009, Pages 2781-2788

  Lapp, Harald ^a   Mitrovic, Veselin ^b   Franz, Norbert ^c   Heuer, Hubertus ^d   Buerke, Michael ^e   Wolfertz, Judith ^f   Mueck, Wolfgang ^g   Unger, Sigrun ^g   Wensing, Georg ^g   Frey, Reiner ^g  

^a HELIOS KLINIKUM ERFURT   (Germany)

^b KERCKHOFF HEART CENTER   (Germany)

^c Schüchtermann Clinic Bad Rothenfelde   (Germany)

^d ST JOHANNES HOSPITAL   (Germany)

^e MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^f HELIOS KLINIKUM WUPPERTAL   (Germany)

^g BAYER PHARMA AG   (Germany)

Author keywords

Drugs; Heart failure; Hemodynamics; Nitric oxide; Vasodilation

Indexed keywords

4 [[4 CARBOXYBUTYL[2 [(4 PHENETHYLBENZYL)OXY]PHENETHYL]AMINO]METHYL]BENZOIC ACID; CINACIGUAT; GUANYLATE CYCLASE ACTIVATOR; UNCLASSIFIED DRUG; BENZOIC ACID DERIVATIVE; CELL RECEPTOR; GUANYLATE CYCLASE; SOLUBLE GUANYLYL CYCLASE; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; DYSPNEA; FEMALE; HEART FAILURE; HEART HEMODYNAMICS; HEART OUTPUT; HEART RATE; HOT FLUSH; HUMAN; HYPOTENSION; LUNG PRESSURE; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; SOMNOLENCE; SYSTEMIC VASCULAR RESISTANCE; ACUTE DISEASE; BLOOD PRESSURE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; ENZYME ACTIVATION; HEMODYNAMICS; INTRAVENOUS DRUG ADMINISTRATION; LUNG WEDGE PRESSURE; MIDDLE AGED; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL; VASCULAR RESISTANCE;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; BENZOIC ACIDS; BLOOD PRESSURE; CARDIAC OUTPUT; ENZYME ACTIVATION; FEMALE; GUANYLATE CYCLASE; HEART FAILURE; HEART RATE; HEMODYNAMICS; HUMANS; HYPOTENSION; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PULMONARY WEDGE PRESSURE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; VASCULAR RESISTANCE; VASODILATOR AGENTS;

EID: 67649229211     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.108.800292     Document Type: Article

References (30)

1. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, Tavazzi L, Smiseth OA, Gavazzi A, Haverich A, Hoes A, Jaarsma T, Korewicki J, Levy S, Linde C, Lopez-Sendon JL, Nieminen MS, Pierard L, Remme WJ. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26:1115-1140.
2. Cleland JG, Khand A, Clark A. The heart failure epidemic: exactly how big is it? N Engl J Med. 2001;22:623-626.
3. McMurray JJ, Petrie MC, Murdoch DR, Davie AP. Clinical epidemiology of heart failure: public and private health burden. Eur Heart J. 1998; 19(suppl):P9-P16.
4. McMurray J, McDonagh T, Morrison CE, Dargie HJ. Trends in hospitalization for heart failure in Scotland 1980-1990. Eur Heart J. 1993;14: 1158-1162.
5. Masoudi FA, Havranek EP, Krumholz HM. The burden of chronic congestive heart failure in older persons: magnitude and implications for policy and research. Heart Fail Rev. 2002;7:9-16.
6. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, Murabito JM, Vasan RS. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347:1397-1402.
7. McBride BF, White CM. Acute decompensated heart failure: a contemporary approach to pharmacotherapeutic management. Pharmacotherapy. 2003;23:997-1020.
8. Lip GY, Pearce LA, Chin BS, Conway DS, Hart RG. Effects of congestive heart failure on plasma von Willebrand factor and soluble P-selectin concentrations in patients with non-valvar atrial fibrillation. Heart. 2005;91:759-763.
9. Moro MA, Russel RJ, Cellek S, Lizasoain I, Su Y, Darley-Usmar VM, Radomski MW, Moncada S. cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase. Proc Natl Acad Sci U S A. 1996;93:1480-1485.
10. Munzel T, Genth-Zotz S, Hink U. Targeting heme-oxidized soluble guanylate cyclase: solution for all cardiorenal problems in heart failure? Hypertension. 2007;49:974-976.
11. Evgenov OV, Pacher P, Schmidt PM, Hasko G, Schmidt HH, Stasch JP. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov. 2006;5: 755-768.
12. Stasch JP, Schmidt PM, Nedvetsky PI, Nedvetskaya TY, H SA, Meurer S, Deile M, Taye A, Knorr A, Lapp H, Muller H, Turgay Y, Rothkegel C, Tersteegen A, Kemp-Harper B, Muller-Esterl W, Schmidt HH. Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest. 2006;116:2552-2561.
13. Roy B, Mo E, Vernon J, Garthwaite J. Probing the presence of the ligand-binding haem in cellular nitric oxide receptors. Br J Pharmacol. 2008;153:1495-1504.
14. Schmidt HH, Schmidt PM, Stasch JP. NO-and haem-independent soluble guanylate cyclase activators. Handb Exp Pharmacol. 2009;191:313-341.
15. Boerrigter G, Costello-Boerrigter LC, Cataliotti A, Lapp H, Stasch JP, Burnett JC. Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure. Hypertension. 2007;49:1128-1133.
16. Frey R, Mueck W, Unger S, Artmeier-Brandt U, Weimann G, Wensing G. Pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in healthy male volunteers. J Clin Pharmacol. 2008;48:1400-1410.
17. Publication Committee for the VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287:1531-1540.
18. McCullough PA, Omland T, Maisel AS. B-type natriuretic peptides: a diagnostic breakthrough for clinicians. Rev Cardiovasc Med. 2003;4: 72-80.
19. Mitrovic V, Seferovic PM, Simeunovic D, Ristic AD, Miric M, Moiseyev VS, Kobalava Z, Nitsche K, Forssmann WG, Luss H, Meyer M. Haemodynamic and clinical effects of ularitide in decompensated heart failure. Eur Heart J. 2006;27:2823-2832.
20. Cowie MR, Jourdain P, Maisel A, Dahlstrom U, Follath F, Isnard R, Luchner A, McDonagh T, Mair J, Nieminen M, Francis G. Clinical applications of B-type natriuretic peptide (BNP) testing. Eur Heart J. 2003;24:1710-1718.
21. Chung P, Hermann L. Acute decompensated heart failure: formulating an evidence-based approach to diagnosis and treatment: part I. Mt Sinai J Med. 2006;73:506-515.
22. Onwuanyi A, Taylor M. Acute decompensated heart failure: pathophysiology and treatment. Am J Cardiol. 2007;99:25D-30D.
23. Allen LA, O'Connor CM. Management of acute decompensated heart failure. CMAJ. 2007;176:797-805.
24. Cotter G, Metzkor E, Kaluski E, Faigenberg Z, Miller R, Simovitz A, Shaham O, Marghitay D, Koren M, Blatt A, Moshkovitz Y, Zaidenstein R, Golik A. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet. 1998;351: 389-393.
25. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005;111:1487-1491.
26. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA. 2005;293: 1900-1905.
27. Aaronson KD, Sackner-Bernstein J. Risk of death associated with nesiritide in patients with acutely decompensated heart failure. JAMA. 2006;296:1465-1466.
28. Elkayam U, Bitar F, Akhter MW, Khan S, Patrus S, Derakhshani M. Intravenous nitroglycerin in the treatment of decompensated heart failure: potential benefits and limitations. J Cardiovasc Pharmacol Ther. 2004; 9:227-241.
29. Stasch JP, Schmidt P, Alonso-Alija C, Apeler H, Dembowsky K, Haerter M, Heil M, Minuth T, Perzborn E, Pleiss U, Schramm M, Schroeder W, Schroder H, Stahl E, Steinke W, Wunder F. NO-and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. Br J Pharmacol. 2002; 136:773-783.
30. Warnholtz A, Mollnau H, Heitzer T, Kontush A, Moller-Bertram T, Lavall D, Giaid A, Beisiegel U, Marklund SL, Walter U, Meinertz T, Munzel T. Adverse effects of nitroglycerin treatment on endothelial function, vascular nitrotyrosine levels and cGMP-dependent protein kinase activity in hyperlipidemic Watanabe rabbits. J Am Coll Cardiol. 2002;40:1356-1363.